EQS-News: Formycon AG / Key word: Preliminary Results/Forecast
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds.
EQS-News: Formycon AG / Key word(s): Preliminary Results/ForecastConvincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast 12.04.2024 / 22:15 CET/CESTThe issuer is solely responsible for the content of this announcement.Press release // 12 April 2024 .
Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.